- 0207 299 0388
- Weekday Hours: 10AM - 5PM
*In some cases, if the doctor requires more information, you may be asked to answer follow-up questions or attend a 1-to-1 virtual consultation before a prescription is approved
*In some cases, if the doctor requires more information, you may be asked to answer follow-up questions or attend a 1-to-1 virtual consultation before a prescription is approved
Women who are overweight or obese have larger amounts of the hormone leptin, which is made in adipose
tissue. This may throw off the hormone balance and lower fertility rates. According to studies, 12% to 15%
of couples who struggle with infertility that engage in unprotected sex after a year are still unable to
conceive, and 10% of couples who do not conceive after two years still do not have a live birth.
Women who are overweight or obese have larger amounts of the hormone leptin, which is made in adipose tissue. This may throw off the hormone balance and lower fertility rates. According to studies, 12% to 15% of couples who struggle with infertility that engage in unprotected sex after a year are still unable to conceive, and 10% of couples who do not conceive after two years still do not have a live birth.
Infertility and weight gain are linked with weight being a factor for infertility.
Wegovy aids in weight loss and therefore would help improve pregnancy
outcomes. After the doctor reviews the patient in a consultation, it will
determine if the patient is suitable to use the medication. The patient would
start on the starter dose of 0.25mg if approved for Wegovy.
Infertility and weight gain are linked with weight being a factor for infertility. Wegovy aids in weight loss and therefore would help improve pregnancy outcomes. After the doctor reviews the patient in a consultation, it will determine if the patient is suitable to use the medication. The patient would start on the starter dose of 0.25mg if approved for Wegovy.
Semaglutide, a medication for type 2 diabetes, is marketed under the name Wegovy. Semaglutide are members of the glucagon-like peptide-1 (GLP-1) receptor agonist drug class. These drugs imitate the functions of the GLP-1 hormone, which aids in controlling body weight, food consumption, and hunger. By slowing down the time it takes to digest the food consumed, it makes the person feel fuller for longer which in turn reduces food intake. This accompanied with a healthy lifestyle will lead to successful weight loss outcomes.
Semaglutide may be useful in managing menopausal weight gain, according to studies. Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months,dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group. People who took Ozempic in conjunction with good lifestyle practices like exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different research done by Novo Nordisk, the company that makes semaglutide.
Semaglutide may be useful in managing menopausal weight gain, according to studies. Semaglutide users who took a weekly dose of 2.4 mg for 68 weeks, or roughly 15 months, dropped an average of 35 pounds, or 15% of their body weight, compared to 2.4% for the placebo group. People who took Ozempic in conjunction with good lifestyle practices like exercise and diet lost 9.3 to 14.1 pounds over a 40-week period, according to different research done by Novo Nordisk, the company that makes semaglutide.
Before recommending Wegovy for weight control, medical professionals will evaluate a number of aspects, including general health and BMI. If the patient meets the eligibility requirements and the medicine is deemed appropriate for managing their weight, they can be prescribed Wegovy. There maybe a few factors preventing the prescribing of Wegovy such as Thyroid cancer or any medical conditions which could be a health risk. The patient must be reviewed by a healthcare professional to be reviewed for the suitability of the medication.
Read our articles on Wegovy & Mounjaro if you would like to learn more about the benefits, the research and case studies.
Some people experience improved fertility after losing weight with Wegovy. Weight loss can restore hormonal balance, improve ovulation, and enhance sperm quality, though Wegovy is not a fertility drug.
Yes. Weight loss and better metabolic health from Wegovy may improve testosterone levels, sperm count, and motility by reducing inflammation and insulin resistance.
Yes. Even without PCOS, improving insulin function can help restore ovulation and hormone balance, which may improve fertility.
Yes. As insulin levels normalise, testosterone levels often drop, which can help restart regular ovulation in women with androgen excess.
Yes. Wegovy lowers inflammation associated with obesity and insulin resistance, which may support better reproductive health.
No. There’s not enough data on whether Wegovy passes into breast milk, so it should be avoided during breastfeeding.
Yes. Many couples conceive naturally after achieving a healthy weight and balanced hormones with medications like Wegovy.
Wegovy should be discontinued before starting fertility treatments. However, weight loss from Wegovy may improve the response to fertility medications later.
Yes, many users see decreased CRP levels, signalling reduced systemic inflammation that supports reproductive health.
Wegovy does not directly change AMH levels. However, by improving insulin resistance and promoting weight loss, it may indirectly support ovarian function and overall fertility.
Book an Appointment Today
Sign-up using your e-mail to regularly receive useful
& interesting weight loss information!
By clicking signup you agree to our Privacy Policy and Terms of Use
All consultations and prescriptions are carried out by GMC registered medical practitioners.
All dispensing and shipping of medicines are completed by a UK licensed, GPhC registered Pharmacy no: 9011284.
CloudRx is our partner pharmacy and prescribing service.
*Disclaimer: Results may vary from person to person depending on individual engagement and commitment to the programme.
The content of this website is provided for general informational purposes only and is not intended as, nor should it be considered a substitute for, professional medical advice. Do not use the information on this website for diagnosing or treating any medical or health related condition. If you have or suspect you have a medical problem, promptly contact your healthcare provider.
© 2025 The London Obesity Clinic
